This women's health discussion skips the hormone facts

What did @therinpy_with_erin_washington actually say?

Comedian René Joseph made several sweeping claims in this clip. He argued that hormone replacement therapy can help conditions including endometriosis, adenomyosis, perimenopause, and menopause. He suggested that anti-trans legislation is a "backdoor" strategy to restrict hormone access for women broadly. He also pointed out that clinical trials have historically centered male participants, leaving women's health understudied. These are big claims, and they land somewhere between genuinely correct, oversimplified, and speculative, depending on which one you're looking at.

The video is tagged under TRT, which is a bit off, since the discussion is about women's hormone therapy, not testosterone replacement for hypogonadism. That framing matters because the clinical evidence base for HRT in women looks very different from the TRT literature.

Does the science back this up?

On the clinical trials point, Joseph is largely right, and the data is damning. The NIH Revitalization Act of 1993 required inclusion of women in federally funded trials, but implementation has been uneven. Yes, HRT has documented uses in menopause and perimenopause symptom management. For endometriosis and adenomyosis, the picture is more complicated.

HRT as a blanket treatment for endometriosis is not standard of care. Progestins and GnRH agonists are more commonly used. Some hormonal therapies overlap, but calling HRT a clear solution for endometriosis overstates what the evidence shows. A 2022 review by Guo et al. in Frontiers in Endocrinology noted that estrogen-containing HRT can actually exacerbate endometriosis in some postmenopausal patients. The anti-trans legislation claim is a political argument, not a clinical one. It may be plausible as a structural critique, but it is not something a peer-reviewed study can confirm or deny.

What did they get wrong (or right)?

Joseph gets real credit for flagging the sex gap in clinical research. That gap is well-documented. Woitowich et al. (2020, eLife) found that even after decades of NIH policy requiring female inclusion, male bias in preclinical research persisted significantly across multiple fields. He also correctly identifies that perimenopausal symptoms are underdiagnosed and undertreated, which is supported by survey data from the Menopause Society.

Where he slips is on HRT and endometriosis. Framing HRT as something that broadly "helps with endometriosis" is not accurate without major qualification. Estrogen therapy can stimulate endometrial tissue, which is the last thing you want if you have active endometriosis. His broader political argument about legislation and bodily control is a legitimate social critique, but presenting it as a direct clinical mechanism overstates what we can actually demonstrate. Conflating political motivation with clinical outcome is a rhetorical move, not a medical finding.

What should you actually know?

If you are considering HRT for perimenopause or menopause, the evidence base is solid and growing. The 2022 Menopause Society position statement supports individualized HRT for symptom management in appropriate candidates, noting that for women under 60 or within 10 years of menopause onset, benefits generally outweigh risks.

For endometriosis and adenomyosis, the treatment picture is different. First-line hormonal options typically include progestins, combined oral contraceptives, or GnRH agonists, not standard menopausal HRT. If you have been diagnosed with either condition, talk to a gynecologist who specializes in it, because the wrong hormone protocol can make symptoms worse, not better.

The point about male-dominated clinical trials deserves more attention than it usually gets. Women have historically been excluded from trials partly due to concerns about hormonal variability and liability around pregnancy, which means dosing guidelines for many drugs were built on male data and extrapolated to women. That is a real problem with real consequences, and Joseph is right to call it out, even if his solutions are vague.